Lysophosphatidylcholine potentiates phenylephrine responses in rat mesenteric arterial bed through modulation of thromboxane A2

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 1, 2006, Pages 355-361

  Zhang, Rui ^a   Rodrigues, Brian ^a   MacLeod, Kathleen M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLCHOLINE; INDOMETACIN; LYSOPHOSPHATIDYLCHOLINE; PHENYLEPHRINE; THROMBOXANE A2; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME IMMUNOASSAY; MALE; MESENTERIC ARTERY; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; VASODILATATION;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; LYSOPHOSPHATIDYLCHOLINES; MALE; MESENTERIC ARTERIES; NITRIC OXIDE; PHENYLEPHRINE; RATS; RATS, WISTAR; THROMBOXANE A2; VASCULAR RESISTANCE; VASODILATION;

EID: 33645120315     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.097964     Document Type: Article

References (39)

1. Ally AI and Horrobin DF (1980) Thromboxane A2 in blood vessel walls and its physiological significance: relevance to thrombosis and hypertension. Prostaglandins Med 4:431-438.
2. Bassa BV, Roh DD, Vaziri ND, Kirschenbaum MA, and Kamanna VS (1999) Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLC-gamma-1 and tyrosine kinase-Ras pathways. Am J Physiol 277:F328-F337.
3. Bolla M, Matrougui K, Loufrani L, Maclouf J, Levy B, Levy-Toledano S, Habib A, and Henrion D (2002) p38 Mitogen-activated protein kinase activation is required for thromboxane-induced contraction in perfused and pressurized rat mesenteric resistance arteries. J Vasc Res 39:353-360.
4. Caveney SW, Culhane JM, Taylor DA, and Fleming WW (1998) Preparation and application of an isolated superior mesenteric arterial vascular preparation. J Cardiovasc Pharmacol 32:721-727.
5. Ceylan A, Karasu C, Aktan F, and Ozansoy G (2004) Simvastatin treatment restores vasoconstriction and the inhibitory effect of LPC on endothelial relaxation via affecting oxidizing metabolism in diabetic rats. Diabetes Nutr Metab 17:203-210.
6. Cowan CL and Steffen RP (1995) Lysophosphatidylcholine inhibits relaxation of rabbit abdominal aorta mediated by endothelium-derived nitric oxide and endothelium-derived hyperpolarizing factor independent of protein kinase C activation. Arterioscler Thromb Vasc Biol 15:2290-2297.
7. Cusma-Pelogia N, Oliveira SF, Nigro D, de Carvalho MH, Scivoletto R, and Fortes ZB (1993) Endothelium inactivation in in vitro perfused vascular beds. Comparison of methods. J Pharmacol Toxicol Methods 29:157-163.
8. Dogne JM, Hanson J, de Leval X, Masereel B, Kolh P, and Pirotte B (2004) New developments on thromboxane modulators. Mini Rev Med Chem 4:649-657.
9. Froese DE, McMaster J, Man RY, Choy PC, and Kroeger EA (1999) Inhibition of endothelium-dependent vascular relaxation by lysophosphatidylcholine: impact of lysophosphatidylcholine on mechanisms involving endothelium-derived nitric oxide and endothelium derived hyperpolarizing factor. Mol Cell Biochem 197:1-6.
10. Fukao M, Hattori Y, Kanno M, Sakuma I, and Kitabatake A (1995) Evidence for selective inhibition by lysophosphatidylcholine of acetylcholine-induced endothelium-dependent hyperpolarization and relaxation in rat mesenteric artery. Br J Pharmacol 116:1541-1543.
11. Galle J, Mameghani A, Bolz SS, Gambaryan S, Gorg M, Quaschning T, Raff U, Barth H, Seibold S, Wanner C, et al. (2003) Oxidized LDL and its compound lysophosphatidylcholine potentiate AngII-induced vasoconstriction by stimulation of RhoA. J Am Soc Nephrol 14:1471-1479.
12. He Y and MacLeod KM (2002) Modulation of noradrenaline-induced vasoconstriction in isolated perfused mesenteric arterial beds from obese Zucker rats in the presence and absence of insulin. Can J Physiol Pharmacol 80:171-179.
13. Koba S, Pakala R, Watanabe T, Katagiri T, and Benedict CR (2000) Synergistic interaction between thromboxane A2 and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation. Prostaglandins Leukot Essent Fatty Acids 63:329-335.
14. Kohno M, Ohmori K, Wada Y, Kondo I, Noma T, Fujita N, Mizushige K, and Mandal AK (2001) Inhibition by eicosapentaenoic acid of oxidized-LDL- and lysophosphatidylcholine-induced human coronary artery smooth muscle cell production of endothelin. J Vasc Res 38:379-388.
15. McCulloch AI and Randall MD (1996) Modulation of vasorelaxant responses to potassium channel openers by basal nitric oxide in the rat isolated superior mesenteric arterial bed. Br J Pharmacol 117:859-866.
16. Menon NK and Bing RJ (1991) Nitroarginine does not inhibit lysophosphatidylcholine (LPC)-induced vascular relaxation and accumulation of cyclic GMP. Proc Soc Exp Biol Med 196:461-463.
17. Muller B (1991) Pharmacology of thromboxane A2, prostacyclin and other eicosanoids in the cardiovascular system. Therapie 46:217-221.
18. Naseem KM (2005) The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 26:33-65.
19. Nishio E, Nakata H, Arimura S, and Watanabe Y (1996) alpha-1-Adrenergic receptor stimulation causes arachidonic acid release through pertussis toxin-sensitive GTP-binding protein and JNK activation in rabbit aortic smooth muscle cells. Biochem Biophys Res Commun 219:277-282.
20. Parmentier JH, Gandhi GK, Wiggins MT, Saeed AE, Bourgoin SG, and Malik KU (2004) Protein kinase Czeta regulates phospholipase D activity in rat-1 fibroblasts expressing the alpha1A adrenergic receptor. BMC Cell Biol 5:4.
21. Rikitake Y, Hirata K, Kawashima S, Inoue N, Akita H, Kawai Y, Nakagawa Y, and Yokoyama M (2000) Inhibition of endothelium-dependent arterial relaxation by oxidized phosphatidylcholine. Atherosclerosis 152:79-87.
22. Ruan Y, Kan H, Parmentier JH, Fatima S, Allen LF, and Malik KU (1998) Alpha-1A Adrenergic receptor stimulation with phenylephrine promotes arachidonic acid release by activation of phospholipase D in rat-1 fibroblasts: inhibition by protein kinase A. J Pharmacol Exp Ther 284:576-585.
23. Seeger W, Walter H, Suttorp N, Muhly M, and Bhakdi S (1989) Thromboxane-mediated hypertension and vascular leakage evoked by low doses of Escherichia coli hemolysin in rabbit lungs. J Clin Investig 84:220-227.
24. Shi AH, Yoshinari M, Wakisaka M, Iwase M, and Fujishima M (1999) Lysophosphatidylcholine molecular species in low density lipoprotein of type 2 diabetes. Horm Metab Res 31:283-286.
25. Shiokoshi T, Ohsaki Y, Kawabe J, Fujino T, and Kikuchi K (2002) Downregulation of nitric oxide accumulation by cyclooxygenase-2 induction and thromboxane A2 production in interleukin-1beta-stimulated rat aortic smooth muscle cells. J Hypertens 20:455-461.
26. Sonoki K, Iwase M, Iino K, Ichikawa K, Ohdo S, Higuchi S, Yoshinari M, and Iida M (2003) Atherogenic role of lysophosphatidylcholine in low-density lipoprotein modified by phospholipase A2 and in diabetic patients: protection by nitric oxide donor. Metabolism 52:308-314.
27. Suenaga H and Kamata K (2003) Lysophosphatidylcholine activates extracellular-signal-regulated protein kinase and potentiates vascular contractile responses in rat aorta. J Pharmacol Sci 92:348-358.
28. Takahara N, Kashiwagi A, Nishio Y, Harada N, Kojima H, Maegawa H, Hidaka H and Kikkawa R (1997) Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells. Diabetologia 40:662-670.
29. Tatchum-Talom R and Atkinson J (1997) Disruption of the rat mesenteric arterial bed endothelial function by air perfusion. Life Sci 60:2407-2416.
30. Terasawa K, Nakajima T, Iida H, Iwasawa K, Oonuma H, Jo T, Morita T, Nakamura F, Fujimori Y, Toyo-oka T, et al. (2002) Nonselective cation currents regulate membrane potential of rabbit coronary arterial cell: modulation by lysophosphatidylcholine. Circulation 106:3111-3119.
31. Terzic A, Puceat M, Vassort G, and Vogel SM (1993) Cardiac alpha 1-adrenoceptors: an overview. Pharmacol Rev 45:147-175.
32. Tokumura A (2004) Metabolic pathways and physiological and pathological significances of lysolipid phosphate mediators. J Cell Biochem 92:869-881.
33. Vane JR and Botting RM (1995) Pharmacodynamic profile of prostacyclin. Am J Cardiol 75:3A-10A.
34. Vuong TD, de Kimpe S, de Roos R, Rabelink TJ, Koomans HA, and Joles JA (2001) Albumin restores lysophosphatidylcholine-induced inhibition of vasodilation in rat aorta. Kidney Int 60:1088-1096.
35. Wolf A, Saito T, Dudek R, and Bing RJ (1991) The effect of lysophosphatidylcholine on coronary and renal circulation in the rabbit. Lipids 26:223-226.
36. Xu Y (2002) Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. Biochim Biophys Acta 1582:81-88.
37. Yuan Y, Schoenwaelder SM, Salem HH, and Jackson SP (1996) The bioactive phospholipid, lysophosphatidylcholine, induces cellular effects via G-protein-dependent activation of adenylyl cyclase. J Biol Chem 271:27090-27098.
38. Zembowicz A, Jones SL, and Wu KK (1995a) Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Investig 96:1688-1692.
39. Zembowicz A, Tang JL, and Wu KK (1995b) Transcriptional induction of endothelial nitric-oxide synthase type III by lysophosphatidylcholine. J Biol Chem 270:17006-17010.